33
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants

      1 , 2 , 3
      Health Affairs
      Health Affairs (Project Hope)

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="P1">Few patients with opioid use disorder receive medication for addiction treatment. In 2017, the Comprehensive Addiction and Recovery Act enabled nurse practitioners (NPs) and physician assistants (PAs) to obtain federal waivers that allowed them to prescribe buprenorphine, a key medication for opioid use disorder. The waiver expansion was intended to increase patient access to opioid use treatment, which was particularly important for rural areas with few physicians. However, little is known about adoption of these waivers by NPs or PAs in rural areas. Using federal data, we examined waiver adoption in rural areas and its association with scope of practice regulations, which set the extent to which NPs or PAs can prescribe medication. From 2016 to 2019, the number of waivered clinicians per 100,000 population in rural areas increased by 111 percent. NPs and PAs accounted for more than half of this increase and were the first waivered clinicians in 285 rural counties with 5.7 million residents. In rural areas, broad scope of practice regulations were associated with twice as many waivered NPs per 100,000 population as restricted scopes of practice were. The rapid growth in the numbers of NPs and PAs with buprenorphine waivers is a promising development in improving access to addiction treatment in rural areas. </p>

          Related collections

          Most cited references12

          • Record: found
          • Abstract: found
          • Article: not found

          Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update

          Opioid use disorder (OUD) is a substantial public health problem. Buprenorphine is an effective medication-assisted treatment (MAT) for OUD, but access is difficult for patients, especially in rural locations. To improve access, the Comprehensive Addiction and Recovery Act of 2016 extended the ability to get a Drug Enforcement Administration (DEA) waiver to prescribe buprenorphine to treat OUD to nurse practitioners (NPs) and physician assistants (PAs). This study summarizes the geographic distribution of waivered physicians, NPs, and PAs at the end of 2017 and compares it to the distribution of waivered physicians 5 years earlier.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found
            Is Open Access

            Policy Pathways to Address Provider Workforce Barriers to Buprenorphine Treatment

            At least 2.3 million people in the U.S. have an opioid use disorder, less than 40% of whom receive evidence-based treatment. Buprenorphine used as part of medication-assisted treatment has high potential to address this gap because of its approval for use in non-specialty outpatient settings, effectiveness at promoting abstinence, and cost effectiveness. However, less than 4% of licensed physicians are approved to prescribe buprenorphine for opioid use disorder, and approximately 47% of counties lack a buprenorphine-waivered physician. Existing policies contribute to workforce barriers to buprenorphine provision and access. Providers are reticent to prescribe buprenorphine because of workforce barriers, such as (1) insufficient training and education on opioid use disorder treatment, (2) lack of institutional and clinician peer support, (3) poor care coordination, (4) provider stigma, (5) inadequate reimbursement from private and public insurers, and (6) regulatory hurdles to obtain the waiver needed to prescribe buprenorphine in non-addiction specialty treatment settings. Policy pathways to addressing these provider workforce barriers going forward include: providing free and easy to access education for providers about opioid use disorders and medication-assisted treatment, eliminating buprenorphine waiver requirements for those licensed to prescribe controlled substances, enforcing insurance parity requirements, requiring coverage of evidence-based medication-assisted treatment as essential health benefits, and providing financial incentives for care coordination across healthcare professional types—including behavioral health counselors and other non-physicians in specialty and non-specialty settings.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Why aren't physicians prescribing more buprenorphine?

              Background & Objective Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently. Methods Physicians (n=558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association Listervs. Results and Conclusions A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing ( 2 (4) = 73.18, p < .001); main reasons were lack of belief in agonist treatment (or 3.98, 95% CI, 1.43 to 11.1, p = .008), lack of time for additional patients (or 5.54, 95% CI, 3.5 to 8.7, p < .001), and belief that reimbursement rates are insufficient (or 2.50, 95% CI, 1.3 to 4.8, p = .006). Differences between non-waivered and waivered physicians concerning attitudes toward buprenorphine treatment as well as resources that would increase willingness to prescribe are also discussed. Identifying barriers to buprenorphine utilization is crucial in expanding treatment options for individuals with OUD.
                Bookmark

                Author and article information

                Journal
                Health Affairs
                Health Affairs
                Health Affairs (Project Hope)
                0278-2715
                1544-5208
                December 01 2019
                December 01 2019
                : 38
                : 12
                : 2048-2056
                Affiliations
                [1 ]Michael L. Barnett () is an assistant professor of health policy and management in the Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, and a primary care physician at Brigham and Women’s Hospital, both in Boston, Massachusetts.
                [2 ]Dennis Lee is a research assistant in the Department of Health Policy and Management, Harvard T. H. Chan School of Public Health.
                [3 ]Richard G. Frank is the Margaret T. Morris Professor of Health Economics in the Department of Health Care Policy, Harvard Medical School, in Boston.
                Article
                10.1377/hlthaff.2019.00859
                6938159
                31794302
                7ca4100a-4f9e-4e39-b32a-dbf2d7ac8149
                © 2019
                History

                Comments

                Comment on this article